Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Inclusion Criteria:

A diagnosis of definite or probable IPF within 5 years of the screening visit, as defined by Figure 3, Tables 4-6 of the ATS/ERS/JRS/ALAT Diagnostic Guidelines (Raghu et al 2011)
FVC 40-90% predicted (inclusive)
DLCO, corrected for hemoglobin, 25-79% predicted (inclusive)
FEV1/FVC >70%
Unlikely to die from cause other than IPF within the next 3 years, in the opinion of the investigator
Unlikely to undergo lung transplantation during this trial

Exclusion Criteria:

Emphysema > fibrosis on screening HRCT (must be confirmed by central reader)
History of major organ, hematopoietic stem cell or bone marrow transplant
Clinically diagnosed AE-IPF or other significant clinical worsening within 3 months of randomization
New York Heart Association (NYHA) class III/IV Congestive Heart Failure (CHF), Ejection Fraction (EF) <25%
Current smoker
Prior use of any B-cell depleting therapy (e.g., rituximab, ofatumumab, or other anti-CD20 mAb, anti-CD40, anti-CD19,anti-CD22 mAb, anti-CD52 mAb, or anti-BAFF mAb)

Other protocol-defined inclusion/exclusion criteria may apply.